| Literature DB >> 33662288 |
Philippe Moreau1, Shaji K Kumar2, Jesús San Miguel3, Faith Davies4, Elena Zamagni5, Nizar Bahlis6, Heinz Ludwig7, Joseph Mikhael8, Evangelos Terpos9, Fredrik Schjesvold10, Thomas Martin11, Kwee Yong12, Brian G M Durie13, Thierry Facon14, Artur Jurczyszyn15, Surbhi Sidana16, Noopur Raje17, Niels van de Donk18, Sagar Lonial19, Michele Cavo5, Sigurdur Y Kristinsson20, Suzanne Lentzsch21, Roman Hajek22, Kenneth C Anderson23, Cristina João24, Hermann Einsele25, Pieter Sonneveld26, Monika Engelhardt27, Rafael Fonseca28, Annette Vangsted29, Katja Weisel30, Rachid Baz31, Vania Hungria32, Jesus G Berdeja33, Fernando Leal da Costa34, Angelo Maiolino35, Anders Waage36, David H Vesole37, Enrique M Ocio38, Hang Quach39, Christoph Driessen40, Joan Bladé41, Xavier Leleu42, Eloisa Riva43, Peter Leif Bergsagel28, Jian Hou44, Wee Joo Chng45, Ulf-Henrik Mellqvist46, Dominik Dytfeld47, Jean-Luc Harousseau48, Hartmut Goldschmidt49, Jacob Laubach23, Nikhil C Munshi23, Francesca Gay50, Meral Beksac51, Luciano J Costa52, Martin Kaiser53, Parameswaran Hari54, Mario Boccadoro50, Saad Z Usmani52, Sonja Zweegman18, Sarah Holstein55, Orhan Sezer56, Simon Harrison57, Hareth Nahi58, Gordon Cook59, Maria-Victoria Mateos60, S Vincent Rajkumar2, Meletios A Dimopoulos9, Paul G Richardson23.
Abstract
This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.Entities:
Year: 2021 PMID： 33662288 DOI： 10.1016/S1470-2045(20)30756-7
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316